The IL-1 cytokine family and its role in inflammation and fibrosis in the lung

Seminars in Immunopathology

Volumn 38, Issue 4, 2016, Pages 517-534

  Borthwick, L A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Fibroblast; Fibrosis; IL 1; IL 18; IL 33; Inflammation; Lung

Indexed keywords

CASPASE 7; CRYOPYRIN; CYTOKINE; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 3; INTERLEUKIN 33; INTERLEUKIN 36; INTERLEUKIN 36 RECEPTOR ALPHA; INTERLEUKIN 37; INTERLEUKIN 38; INTERLEUKIN 4; SOMATOSTATIN RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; INTERLEUKIN 1 RECEPTOR;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA SEQUENCE; HUMAN; IMMUNOPATHOGENESIS; LUNG FIBROSIS; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RNA INTERFERENCE; UPREGULATION; ANIMAL; FIBROSIS; GENETICS; INFLAMMATION; LUNG DISEASES; METABOLISM; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; FIBROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; LUNG DISEASES; RECEPTORS, INTERLEUKIN-1; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84961801288     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-016-0559-z     Document Type: Review

References (248)

1. Mannino DM, Kiriz VA (2006) Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis 1:219–233
2. Borthwick LA, Wynn TA, Fisher AJ (1832) Cytokine mediated tissue fibrosis. Biochim Biophys Acta 2013:1049–1060
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653
4. Coward WR, Saini G, Jenkins G (2010) The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 4:367–388
5. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39:1003–1018
6. Menkin V (1943) Studies on the isolation of the factor responsible for tissue injury in inflammation. Science 97:165–167
7. Dinarello CA, Renfer L, Wolff SM (1977) Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A 74:4624–4627
8. Rosenwasser LJ, Dinarello CA, Rosenthal AS (1979) Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 150:709–714
9. Mizel SB, Oppenheim JJ, Rosentreich DL (1978) Characterization of lymphocyte-activating factor (LAF) produced by a macrophage cell line, P388D1. II. Biochemical characterization of LAF induced by activated T cells and LPS. J Immunol 120:1504–1508
10. (1979) Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors. J Immunol 123:2928–2929
11. Lomedico PT, Gubler U, Hellmann CP, Dukovich M, Giri JG, Pan YC et al (1984) Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312:458–462
12. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM et al (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 81:7907–7911
13. Modi WS, Masuda A, Yamada M, Oppenheim JJ, Matsushima K, O’Brien SJ (1988) Chromosomal localization of the human interleukin 1 alpha (IL-1 alpha) gene. Genomics 2:310–314
14. Dower SK, Kronheim SR, Hopp TP, Cantrell M, Deeley M, Gillis S et al (1986) The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature 324:266–268
15. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T (1993) Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem 268:22100–22104
16. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y et al (2004) The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 101:2434–2439
17. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550
18. Martin TR, Hagimoto N, Nakamura M, Matute-Bello G (2005) Apoptosis and epithelial injury in the lungs. Proc Am Thorac Soc 2:214–220
19. Vareille M, Kieninger E, Edwards MR, Regamey N (2011) The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 24:210–229
20. Calderon-Garciduenas L, Osnaya N, Rodriguez-Alcaraz A, Villarreal-Calderon A (1997) DNA damage in nasal respiratory epithelium from children exposed to urban pollution. Environ Mol Mutagen 30:11–20
21. Rabinovici R, Neville LF, Abdullah F, Phillip DR, Vernick J, Fong KL et al (1995) Aspiration-induced lung injury: role of complement. Crit Care Med 23:1405–1411
22. Pauwels NS, Bracke KR, Dupont LL, Van Pottelberge GR, Provoost S, Vanden Berghe T et al (2011) Role of IL-1alpha and the Nlrp3/caspase-1/IL-1beta axis in cigarette smoke-induced pulmonary inflammation and COPD. Euro Respir J 38:1019–1028
23. Kosmider B, Messier EM, Chu HW, Mason RJ (2011) Human alveolar epithelial cell injury induced by cigarette smoke. PLoS One 6, e26059
24. Aoshiba K, Nagai A (2003) Oxidative stress, cell death, and other damage to alveolar epithelial cells induced by cigarette smoke. Tob Induc Dis 1:219–226
25. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR et al (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 107:2574–2579
26. Luheshi NM, McColl BW, Brough D (2009) Nuclear retention of IL-1 alpha by necrotic cells: a mechanism to dampen sterile inflammation. Eur J Immunol 39:2973–2980
27. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13:851–856
28. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E et al (2011) IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 187:4835–4843
29. Dagvadorj J, Shimada K, Chen S, Jones HD, Tumurkhuu G, Zhang W et al (2015) Lipopolysaccharide induces alveolar macrophage necrosis via CD14 and the P2X7 receptor leading to interleukin-1alpha release. Immunity 42:640–653
30. Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I et al (2010) Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 107:19449–19454
31. Sung SS, Walters JA (1991) Increased cyclic AMP levels enhance IL-1 alpha and IL-1 beta mRNA expression and protein production in human myelomonocytic cell lines and monocytes. J Clin Invest 88:1915–1923
32. Brody DT, Durum SK (1989) Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. J Immunol 143:1183–1187
33. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaiser E, Brett J et al (1992) Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333–2339
34. Rider P, Carmi Y, Voronov E, Apte RN (2013) Interleukin-1alpha. Semin Immunol 25:430–438
35. Piccioli P, Rubartelli A (2013) The secretion of IL-1beta and options for release. Semin Immunol 25:425–429
36. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732
37. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426
38. Fantuzzi G, Ku G, Harding MW, Livingston DJ, Sipe JD, Kuida K et al (1997) Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol 158:1818–1824
39. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H et al (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 60:3651–3662
40. Rubartelli A, Cozzolino F, Talio M, Sitia R (1990) A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J 9:1503–1510
41. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A (1999) The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 10:1463–1475
42. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci U S A 101:9745–9750
43. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15:825–835
44. Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M et al (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J Immunol 174:7268–7277
45. Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 179:1913–1925
46. Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 7:99–109
47. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC (1991) Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A 88:5232–5236
48. Palomo J, Dietrich D, Martin P, Palmer G, Gabay C (2015) The interleukin (IL)-1 cytokine family - Balance between agonists and antagonists in inflammatory diseases. Cytokine 76:25–37
49. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266:10331–10336
50. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A et al (1997) A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386:194–200
51. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL et al (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10:2821–2832
52. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 282:11982–11995
53. Symons JA, Young PR, Duff GW (1995) Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 92:1714–1718
54. Yamaki M, Sugiura K, Muro Y, Shimoyama Y, Tomita Y (2010) Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. Exp Dermatol 19:730–735
55. Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L et al (2014) IL-1alpha released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunol 7:684–693
56. Tracy EC, Bowman MJ, Henderson BW, Baumann H (2012) Interleukin-1alpha is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br J Cancer 107:1534–1546
57. Lindroos PM, Coin PG, Badgett A, Morgan DL, Bonner JC (1997) Alveolar macrophages stimulated with titanium dioxide, chrysotile asbestos, and residual oil fly ash upregulate the PDGF receptor-alpha on lung fibroblasts through an IL-1beta-dependent mechanism. Am J Respir Cell Mol Biol 16:283–292
58. Witowski J, Thiel A, Dechend R, Dunkel K, Fouquet N, Bender TO et al (2001) Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. Am J Pathol 158:1441–1450
59. Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH (1988) Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 106:311–318
60. Kahari VM, Heino J, Vuorio E (1987) Interleukin-1 increases collagen production and mRNA levels in cultured skin fibroblasts. Biochim Biophys Acta 929:142–147
61. Xiao H, Ji AM, Li ZL, Song XD, Su D, Chen AH (2008) Interleukin-1beta inhibits collagen synthesis and promotes its decomposition in cultured cardiac fibroblasts. Sheng Li Xue Bao 60:355–361
62. Bhatnagar R, Penfornis H, Mauviel A, Loyau G, Saklatvala J, Pujol JP (1986) Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int 13:709–720
63. Doerner AM, Zuraw BL (2009) TGF-beta1 induced epithelial to mesenchymal transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but not abrogated by corticosteroids. Respir Res 10:100
64. Borthwick LA, McIlroy EI, Gorowiec MR, Brodlie M, Johnson GE, Ward C et al (2010) Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant 10:498–509
65. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J et al (2011) Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A 108:E1475–E1483
66. Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M et al (2010) Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51:1027–1036
67. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J (2001) Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107:1529–1536
68. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S et al (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117:3786–3799
69. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW et al (2010) Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 207:535–552
70. Wilmott RW, Kitzmiller JA, Fiedler MA, Stark JM (1998) Generation of a transgenic mouse with lung-specific overexpression of the human interleukin-1 receptor antagonist protein. Am J Respir Cell Mol Biol 18:429–434
71. Mulrooney N, Jobe AH, Ikegami M (2004) Lung inflammatory responses to intratracheal interleukin-1alpha in ventilated preterm lambs. Pediatr Res 55:682–687
72. Hybertson BM, Jepson EK, Allard JD, Cho OJ, Lee YM, Huddleston JR et al (2003) Transforming growth factor beta contributes to lung leak in rats given interleukin-1 intratracheally. Exp Lung Res 29:361–373
73. Guo JL, Gu NL, Chen J, Shi TM, Zhou Y, Rong Y et al (2013) Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch Toxicol 87:1963–1973
74. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E (1998) Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 41:1798–1805
75. Piguet PF, Vesin C, Grau GE, Thompson RC (1993) Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 5:57–61
76. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R et al (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65:1006–1012
77. Botelho FM, Bauer CM, Finch D, Nikota JK, Zavitz CC, Kelly A et al (2011) IL-1alpha/IL-1R1 expression in chronic obstructive pulmonary disease and mechanistic relevance to smoke-induced neutrophilia in mice. PLoS One 6, e28457
78. Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V et al (2009) Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care 179:903–913
79. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9:847–856
80. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674–677
81. dos Santos G, Rogel MR, Baker MA, Troken JR, Urich D, Morales-Nebreda L et al (2015) Vimentin regulates activation of the NLRP3 inflammasome. Nat Commun 6:6574
82. Sethi JM, Rochester CL (2000) Smoking and chronic obstructive pulmonary disease. Clin Chest Med 21:67–86, viii
83. Kuschner WG, D’Alessandro A, Wong H, Blanc PD (1996) Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 9:1989–1994
84. Keatings VM, Collins PD, Scott DM, Barnes PJ (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153:530–534
85. Wanderer AA (2008) Interleukin-1beta targeted therapy in severe persistent asthma (SPA) and chronic obstructive pulmonary disease (COPD): proposed similarities between biphasic pathobiology of SPA/COPD and ischemia-reperfusion injury. Isr Med Assoc J 10:837–842
86. Yigla M, Berkovich Y, Nagler RM (2007) Oxidative stress indices in COPD--Broncho-alveolar lavage and salivary analysis. Arch Oral Biol 52:36–43
87. Bartziokas K, Papaioannou AI, Loukides S, Papadopoulos A, Haniotou A, Papiris S et al (2014) Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J 43:43–53
88. Eltom S, Stevenson CS, Rastrick J, Dale N, Raemdonck K, Wong S et al (2011) P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 6, e24097
89. Churg A, Zhou S, Wang X, Wang R, Wright JL (2009) The role of interleukin-1beta in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol 40:482–490
90. dos Santos G, Kutuzov MA, Ridge KM (2012) The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol 303:L627–L633
91. Lommatzsch M, Cicko S, Muller T, Lucattelli M, Bratke K, Stoll P et al (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928–934
92. Cicko S, Lucattelli M, Muller T, Lommatzsch M, De Cunto G, Cardini S et al (2010) Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol 185:688–697
93. Barlo NP, van Moorsel CH, Korthagen NM, Heron M, Rijkers GT, Ruven HJ et al (2011) Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis. Clin Exp Immunol 166:346–351
94. Ogushi F, Tani K, Endo T, Tada H, Kawano T, Asano T et al (2001) Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. J Med Invest 48:181–189
95. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN (1993) Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 150:4188–4196
96. Kline JN, Schwartz DA, Monick MM, Floerchinger CS, Hunninghake GW (1993) Relative release of interleukin-1 beta and interleukin-1 receptor antagonist by alveolar macrophages. A study in asbestos-induced lung disease, sarcoidosis, and idiopathic pulmonary fibrosis. Chest 104:47–53
97. Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C et al (2016) NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. Eur Respir J. doi:10.1183/13993003.00564-2015
98. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L et al (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774–783
99. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B (2014) Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349:209–220
100. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A et al (2008) Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 590:400–408
101. Belperio JA, DiGiovine B, Keane MP, Burdick MD, Ying Xue Y, Ross DJ et al (2002) Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 73:591–599
102. Borthwick LA, Corris PA, Mahida R, Walker A, Gardner A, Suwara M et al (2013) TNFalpha from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. Am J Transplant 13:621–633
103. Borthwick LA, Suwara MI, Carnell SC, Green NJ, Mahida R, Dixon D et al (2015) Pseudomonas aeruginosa induced airway epithelial injury drives fibroblast activation: a mechanism in chronic lung allograft dysfunction. Am J Transplant. doi:10.1111/ajt.13690
104. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
105. Baekkevold ES, Roussigne M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F et al (2003) Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163:69–79
106. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 104:282–287
107. Roussel L, Erard M, Cayrol C, Girard JP (2008) Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9:1006–1012
108. Martin MU (2013) Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol 25:449–457
109. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616
110. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP et al (2012) IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109:1673–1678
111. Cayrol C, Girard JP (2009) The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106:9021–9026
112. Ali S, Nguyen DQ, Falk W, Martin MU (2010) Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 391:1512–1516
113. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C et al (2009) Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31:84–98
114. Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M (2012) Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol 132:2593–2600
115. Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S (2009) Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun 387:218–222
116. Ali S, Hubert M, Kollewe C, Bischoff SC, Falk W, Martin MU (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 104:18660–18665
117. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555
118. Hayakawa H, Hayakawa M, Kume A, Tominaga S (2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 282:26369–26380
119. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T et al (2001) Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 285:1377–1383
120. Smith DE (2010) IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 40:200–208
121. Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ (2011) TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 43:1383–1391
122. Polumuri SK, Jayakar GG, Shirey KA, Roberts ZJ, Perkins DJ, Pitha PM et al (2012) Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol 189:50–60
123. Zhao WH, Hu ZQ (2012) Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 58:267–273
124. Cayrol C, Girard JP (2014) IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31:31–37
125. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H et al (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463:540–544
126. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK et al (2010) Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464:1367–1370
127. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ et al (2010) Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 107:11489–11494
128. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA et al (2011) Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12:1045–1054
129. Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M et al (2013) IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol 190:4489–4499
130. Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B (2011) IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 41:1675–1686
131. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S et al (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 183:6469–6477
132. Molofsky AB, Savage AK, Locksley RM (2015) Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity 42:1005–1019
133. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P (2015) Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 354:24–31
134. Li P, Ma H, Han D, Mou K (2015) Interleukin-33 affects cytokine production by keratinocytes in vitiligo. Clin Exp Dermatol 40:163–170
135. Kurokawa M, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M et al (2011) Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 155(Suppl 1):12–20
136. Zhu J, Carver W (2012) Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 58:368–379
137. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K et al (2010) IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 185:5743–5750
138. Gao Q, Li Y, Li M (2015) The potential role of IL-33/ST2 signaling in fibrotic diseases. J Leukoc Biol 98:15–22
139. Luzina IG, Kopach P, Lockatell V, Kang PH, Nagarsekar A, Burke AP et al (2013) Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 49:999–1008
140. Gao Q, Li Y, Pan X, Yuan X, Peng X, Li M (2016) Lentivirus expressing soluble ST2 alleviates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 30:188–193
141. Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L et al (2014) IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134:1422–1432.e1411
142. Luzina IG, Pickering EM, Kopach P, Kang PH, Lockatell V, Todd NW et al (2012) Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 189:403–410
143. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S (2011) Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 30:825–830
144. Qiu C, Li Y, Li M, Li M, Liu X, McSharry C et al (2013) Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice. Immunology 138:76–82
145. Wu H, Yang S, Wu X, Zhao J, Zhao J, Ning Q et al (2014) Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochem Biophys Res Commun 450:110–116
146. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N et al (2015) Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42:566–579
147. Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J et al (2015) Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 308:L619–L627
148. Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X et al (2013) Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123:3967–3982
149. Shang J, Zhao J, Wu X, Xu Y, Xie J, Zhao J (2015) Interleukin-33 promotes inflammatory cytokine production in chronic airway inflammation. Biochem Cell Biol 93:359–366
150. Barnes PJ (2015) Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136:531–545
151. Wang X, Shannahan JH, Brown JM (2014) IL-33 modulates chronic airway resistance changes induced by multi-walled carbon nanotubes. Inhal Toxicol 26:240–249
152. Tiringer K, Treis A, Kanolzer S, Witt C, Ghanim B, Gruber S et al (2014) Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients. Eur Respir J 44:802–805
153. Roussel L, Farias R, Rousseau S (2013) IL-33 is expressed in epithelia from patients with cystic fibrosis and potentiates neutrophil recruitment. J Allergy Clin Immunol 131:913–916
154. Okamura H, Nagata K, Komatsu T, Tanimoto T, Nukata Y, Tanabe F et al (1995) A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 63:3966–3972
155. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA et al (1997) Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275:206–209
156. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A et al (1997) Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386:619–623
157. Dinarello CA, Novick D, Kim S, Kaplanski G (2013) Interleukin-18 and IL-18 binding protein. Front Immunol 4:289
158. Morel JC, Park CC, Woods JM, Koch AE (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 276:37069–37075
159. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA (2004) Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci U S A 101:8815–8820
160. Novick D, Kim S, Kaplanski G, Dinarello CA (2013) Interleukin-18, more than a Th1 cytokine. Semin Immunol 25:439–448
161. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M et al (2000) Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A 97:1190–1195
162. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M (1999) Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127–136
163. Novick D, Schwartsburd B, Pinkus R, Suissa D, Belzer I, Sthoeger Z et al (2001) A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14:334–342
164. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53–72
165. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M et al (1996) Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26:1647–1651
166. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB et al (2005) IL-18-induced CD83 + CCR7+ NK helper cells. J Exp Med 202:941–953
167. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G et al (2001) Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 281:R1264–R1273
168. Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM et al (2002) Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50:812–820
169. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S et al (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108:1825–1832
170. Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY (2001) Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 166:517–521
171. Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT (2001) Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 166:959–965
172. Nakatani-Okuda A, Ueda H, Kashiwamura S, Sekiyama A, Kubota A, Fujita Y et al (2005) Protection against bleomycin-induced lung injury by IL-18 in mice. Am J Physiol Lung Cell Mol Physiol 289:L280–L287
173. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (2009) Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 41:661–670
174. Hoshino T, Kato S, Oka N, Imaoka H, Kinoshita T, Takei S et al (2007) Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med 176:49–62
175. Kang MJ, Choi JM, Kim BH, Lee CM, Cho WK, Choe G et al (2012) IL-18 induces emphysema and airway and vascular remodeling via IFN-gamma, IL-17A, and IL-13. Am J Respir Crit Care Med 185:1205–1217
176. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ et al (2007) Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 56:1787–1797
177. Zhang W, Cong XL, Qin YH, He ZW, He DY, Dai SM (2013) IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation 36:103–109
178. Fix C, Bingham K, Carver W (2011) Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53:19–28
179. Kitasato Y, Hoshino T, Okamoto M, Kato S, Koda Y, Nagata N et al (2004) Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 31:619–625
180. Kang MJ, Homer RJ, Gallo A, Lee CG, Crothers KA, Cho SJ et al (2007) IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol 178:1948–1959
181. Petersen AM, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J et al (2007) Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung 185:161–171
182. Wang J, Liu X, Xie M, Xie J, Xiong W, Xu Y (2012) Increased expression of interleukin-18 and its receptor in peripheral blood of patients with chronic obstructive pulmonary disease. COPD 9:375–381
183. Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C (2009) Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respir Med 103:1056–1062
184. Imaoka H, Hoshino T, Takei S, Kinoshita T, Okamoto M, Kawayama T et al (2008) Interleukin-18 production and pulmonary function in COPD. Eur Respir J 31:287–297
185. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D et al (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 22:127–147
186. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims JE (2000) Four new members expand the interleukin-1 superfamily. J Biol Chem 275:1169–1175
187. Busfield SJ, Comrack CA, Yu G, Chickering TW, Smutko JS, Zhou H et al (2000) Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics 66:213–216
188. Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE et al (2000) Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 275:10308–10314
189. Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, Khandekar S et al (2002) Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 18:61–71
190. Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E et al (2001) IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 13:1–7
191. Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, Dinarello CA et al (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 99:13723–13728
192. Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP et al (2015) IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 16:354–365
193. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014–1022
194. Sharma S, Kulk N, Nold MF, Graf R, Kim SH, Reinhardt D et al (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 180:5477–5482
195. Grimsby S, Jaensson H, Dubrovska A, Lomnytska M, Hellman U, Souchelnytskyi S (2004) Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity. FEBS Lett 577:93–100
196. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S (2004) A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J 18:161–163
197. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB et al (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 108:16711–16716
198. Luo Y, Cai X, Liu S, Wang S, Nold-Petry CA, Nold MF et al (2014) Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A 111:15178–15183
199. Dinarello CA, Bufler P (2013) Interleukin-37. Semin Immunol 25:466–468
200. Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, Blanchard J et al (2012) Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 27:1609–1616
201. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG et al (2014) IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog 10, e1004462
202. Quirk S, Agrawal DK (2014) Immunobiology of IL-37: mechanism of action and clinical perspectives. Expert Rev Clin Immunol 10:1703–1709
203. Raedler D, Ballenberger N, Klucker E, Bock A, Otto R, Prazeres da Costa O et al (2015) Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J Allergy Clin Immunol 135:81–91
204. Charrad R, Berraies A, Hamdi B, Ammar J, Hamzaoui K, Hamzaoui A (2016) Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-alpha, IL-beta, IL-6 and IL-17A. Immunobiology 221(2):182–187. doi:10.1016/j.imbio.2015.09.009.
205. Lunding L, Webering S, Vock C, Schroder A, Raedler D, Schaub B et al (2015) IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy 70:366–373
206. Zhang J, Liu G, Zeng J, Wang W, Xiang W, Kong B et al (2015) Clinical detection and significance of plasma IL-37 in patients with active pulmonary tuberculosis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 31:520–523
207. Huang Z, Gao C, Chi X, Hu YW, Zheng L, Zeng T et al (2015) IL-37 expression is upregulated in patients with tuberculosis and induces macrophages towards an M2-like phenotype. Scand J Immunol 82:370–379
208. Di Stefano A, Caramori G, Barczyk A, Vicari C, Brun P, Zanini A et al (2014) Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax 69:516–524
209. Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10:89–102
210. Abbatt JD, Lea AJ (1956) The incidence of leukaemia in ankylosing spondylitis treated with x-rays. Lancet 271:1317–1320
211. Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA et al (2011) Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 286:42594–42602
212. Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, Gabel CA (2009) Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J Immunol 183:4021–4030
213. Gresnigt MS, van de Veerdonk FL (2013) Biology of IL-36 cytokines and their role in disease. Semin Immunol 25:458–465
214. Li Y, Messina C, Bendaoud M, Fine DH, Schreiner H, Tsiagbe VK (2010) Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Mol Oral Microbiol 25:275–292
215. Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E et al (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood 118:5813–5823
216. Turtoi A, Brown I, Schlager M, Schneeweiss FH (2010) Gene expression profile of human lymphocytes exposed to (211)At alpha particles. Radiat Res 174:125–136
217. Yang J, Meyer M, Muller AK, Bohm F, Grose R, Dauwalder T et al (2010) Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol 188:935–952
218. Debets R, Timans JC, Homey B, Zurawski S, Sana TR, Lo S et al (2001) Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J Immunol 167:1440–1446
219. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 279:13677–13688
220. Vigne S, Palmer G, Martin P, Lamacchia C, Strebel D, Rodriguez E et al (2012) IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells. Blood 120:3478–3487
221. Chustz RT, Nagarkar DR, Poposki JA, Favoreto S Jr, Avila PC, Schleimer RP et al (2011) Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells. Am J Respir Cell Mol Biol 45:145–153
222. Bochkov YA, Hanson KM, Keles S, Brockman-Schneider RA, Jarjour NN, Gern JE (2010) Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma. Mucosal Immunol 3:69–80
223. Vos JB, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS, Datson NA (2005) Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiol Genomics 21:324–336
224. Ramadas RA, Ewart SL, Medoff BD, LeVine AM (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44:134–145
225. Ramadas RA, Ewart SL, Iwakura Y, Medoff BD, LeVine AM (2012) IL-36alpha exerts pro-inflammatory effects in the lungs of mice. PLoS One 7, e45784
226. Gabay C, Towne JE (2015) Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol 97:645–652
227. Parsanejad R, Fields WR, Steichen TJ, Bombick BR, Doolittle DJ (2008) Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells. J Interferon Cytokine Res 28:703–712
228. Magne D, Palmer G, Barton JL, Mezin F, Talabot-Ayer D, Bas S et al (2006) The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 8:R80
229. Derer A, Groetsch B, Harre U, Bohm C, Towne J, Schett G et al (2014) Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLoS One 9, e101954
230. DeVoti JA, Rosenthal DW, Wu R, Abramson AL, Steinberg BM, Bonagura VR (2008) Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis. Mol Med 14:608–617
231. Chen H, Wang Y, Bai C, Wang X (2012) Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J Proteomics 75:2835–2843
232. Lin H, Ho AS, Haley-Vicente D, Zhang J, Bernal-Fussell J, Pace AM et al (2001) Cloning and characterization of IL-1HY2, a novel interleukin-1 family member. J Biol Chem 276:20597–20602
233. Bensen JT, Dawson PA, Mychaleckyj JC, Bowden DW (2001) Identification of a novel human cytokine gene in the interleukin gene cluster on chromosome 2q12-14. J Interferon Cytokine Res 21:899–904
234. Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K (2002) A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 79:718–725
235. Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G et al (2015) Interleukin-36alpha axis is modulated in patients with primary Sjogren’s syndrome. Clin Exp Immunol 181:230–238
236. van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG et al (2012) IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A 109:3001–3005
237. Monnet D, Kadi A, Izac B, Lebrun N, Letourneur F, Zinovieva E et al (2012) Association between the IL-1 family gene cluster and spondyloarthritis. Ann Rheum Dis 71:885–890
238. Lea WI, Lee YH (2012) The associations between interleukin-1 polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis. Jt Bone Spine 79:370–374
239. Yuan X, Peng X, Li Y, Li M (2015) Role of IL-38 and its related cytokines in inflammation. Mediat Inflamm 2015:807976
240. Ottaviani S, Molto A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15:R123
241. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11:633–652
242. Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M (2014) Inflammasomes in respiratory disease: from bench to bedside. Chest 145:1121–1133
243. Haycock JW (2011) 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 695:1–15
244. Morin JP, Baste JM, Gay A, Crochemore C, Corbiere C, Monteil C (2013) Precision cut lung slices as an efficient tool for in vitro lung physio-pharmacotoxicology studies. Xenobiotica 43:63–72
245. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M et al (2001) Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 24:591–598
246. Emblom-Callahan MC, Chhina MK, Shlobin OA, Ahmad S, Reese ES, Iyer EP et al (2010) Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 96:134–145
247. Huang SK, Scruggs AM, McEachin RC, White ES, Peters-Golden M (2014) Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS One 9, e107055
248. Liu X, Sun SQ, Ostrom RS (2005) Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 315:678–687